Page last updated: 2024-11-12
myxochelin b
Description
myxochelin B: isolated from Stigmatella aurantiaca; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
myxochelin B : A member of the class of benzamides obtained by formal condensation of the 1- and 6-amino groups of hexane-1,2,6-triamine with the carboxy groups from two molecules of 2,3-dihydroxybenzoic acid followed by reduction of the amide carbonyl at position 5 to a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 10873133 |
CHEMBL ID | 522025 |
CHEBI ID | 7061 |
SCHEMBL ID | 8364537 |
MeSH ID | M0403754 |
Synonyms (11)
Synonym |
C12221 , |
myxochelin b |
chebi:7061 , |
CHEMBL522025 , |
n-{(2s)-1-amino-6-[(2,3-dihydroxybenzoyl)amino]hexan-2-yl}-2,3-dihydroxybenzamide |
SCHEMBL8364537 |
n-[(5s)-6-amino-5-[(2,3-dihydroxybenzoyl)amino]hexyl]-2,3-dihydroxy-benzamide |
surecn8364537 |
n-[(5s)-6-amino-5-[(2,3-dihydroxybenzoyl)amino]hexyl]-2,3-dihydroxybenzamide |
Q27089364 |
bdbm50530492 |
Roles (2)
Role | Description |
siderophore | Any of low-molecular-mass iron(III)-chelating compounds produced by microorganisms for the purpose of the transport and sequestration of iron. |
bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
catechols | Any compound containing an o-diphenol component. |
benzamides | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (1)
Inhibition Measurements
Biological Processes (30)
Molecular Functions (6)
Ceullar Components (11)
Bioassays (4)
Assay ID | Title | Year | Journal | Article |
AID418507 | Cytotoxicity against mouse 26-L5 cells at 7.5 uM after 24 hrs | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
| Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
AID418505 | Cytotoxicity against mouse 26-L5 cells after 24 hrs | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
| Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
AID418504 | Antiinvasive activity against mouse 26-L5 cells assessed as inhibition of cell invasion by Matrigel assay | 2009 | Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
| Synthesis and evaluation of myxochelin analogues as antimetastatic agents. |
AID1615863 | Inhibition of recombinant human 5-lipoxygenase using arachidonic acid as substrate preincubated for 10 mins followed by susbtrate addition and measured after 10 mins by reverse phase HPLC method | 2019 | Journal of natural products, 09-27, Volume: 82, Issue:9
| Myxochelin- and Pseudochelin-Derived Lipoxygenase Inhibitors from a Genetically Engineered |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.43 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.37 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |